Acquisition by Peter Kiener of 40000 shares of Pieris Pharmaceuticals subject to Rule 16b-3

PIRS Stock  USD 16.84  0.07  0.42%   
Slightly above 71 percent of all Pieris Pharmaceuticals' private investors are curious in acquiring. The analysis of the overall investor sentiment regarding Pieris Pharmaceuticals suggests that a large number of traders are confidant. Pieris Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Pieris Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by Pieris Pharmaceuticals Director . Grant, award or other acquisition pursuant to Rule 16b-3

Read at macroaxis.com
Pieris insider trading alert for acquisition of stock option (right to buy) by Peter Kiener, Director: , on 26th of April 2024. This event was filed by Pieris Pharmaceuticals with SEC on 2022-06-22. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Pieris Pharmaceuticals' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Pieris Pharmaceuticals' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Pieris Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Pieris Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Pieris Pharmaceuticals Fundamental Analysis

We analyze Pieris Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pieris Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pieris Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

EBITDA

EBITDA Comparative Analysis

Pieris Pharmaceuticals is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Pieris Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pieris Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Pieris Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Pieris Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Pieris Pharmaceuticals Related Equities

AFMDAffimed NV   14.50   
0%
100.0%
CKPTCheckpoint Therapeutics   7.47   
0%
51.0%
AGENAgenus   6.29   
0%
43.0%
ADAPAdaptimmune Therapeutics   6.06   
0%
41.0%
CUECue Biopharma   3.92   
0%
27.0%
PDSBPDS Biotechnology   3.83   
0%
26.0%
ADCTADC Therapeutics   2.01   
0%
13.0%
TERNTerns Pharmaceuticals   1.40   
0%
9.0%
ACHLAchilles Therapeutics   0.94   
0%
6.0%
CRVSCorvus Pharmaceuticals   0.22   
1.0%
0%
LPTXLeap Therapeutics   1.18   
8.0%
0%
INZYInozyme Pharma   6.05   
41.0%
0%
XFORX4 Pharmaceuticals   8.11   
55.0%
0%
MREOMereo BioPharma   9.14   
63.0%
0%

Additional Tools for Pieris Stock Analysis

When running Pieris Pharmaceuticals' price analysis, check to measure Pieris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pieris Pharmaceuticals is operating at the current time. Most of Pieris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pieris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pieris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pieris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.